A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...

In December, Novo Nordisk announced that the Food and Drug Administration had approved its once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. It remains the only ...

Thailand’s Public Health Ministry is ramping up efforts to combat the rising obesity rates and the broader issue of NCDs ...

Learn how new oral GLP-1 weight loss pills work, how they compare with injections, and how the next generation of “small ...